Metabolic phenotype and patient characteristics associate with inter-donor variability of osteogenic differentiation in human adipose stem cells.
Sattar A., Beier JP., Ruhl T.
Laboratory Study with a reported sample of 26, published in Biochem Biophys Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Biochem Biophys Rep (2026)
- Country
- Netherlands
- Reported sample size
- 26
- Source database
- PubMed
- PMID
- 42564866
- DOI
- 10.1016/j.bbrep.2026.102728
Abstract (original English)
Adipose-derived stem/stromal cells (ASCs) are promising candidates for bone tissue engineering due to their abundance, accessibility, and osteogenic differentiation capacity. However, substantial inter-donor variability limits their standardized clinical application. This study investigated whether metabolic characteristics and donor-related parameters are associated with ASC osteogenic differentiation potential. ASCs were isolated from human subcutaneous adipose tissue (n = 26) and cultured under osteogenic conditions. Cell viability was evaluated at days 2 and 14, including cell proliferation (crystal violet staining), overall metabolic activity (resazurin conversion), as well as glucose uptake (2-NBDG) and mitochondrial membrane potential (TMRE). Osteogenesis was quantified by alkaline phosphatase activity, calcium deposition, and secretion of SPARC and osteocalcin (BGLAP). Osteogenic induction significantly enhanced osteogenic markers and mineralization across donors and was accompanied by a distinct metabolic phenotype characterized by reduced per-cell metabolic activity and glucose uptake, and elevated mitochondrial membrane potential. Early (day 2) metabolic parameters did not predict subsequent mineralization capacity, whereas metabolic activity at day 14 correlated inversely with calcium deposition. Donor age, body mass index, and blood glucose levels were not associat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.